Tarsus Pharmaceuticals completes acquisition of Alkeus Pharmaceuticals

• Tarsus completed its acquisition of Alkeus, adding worldwide rights to ALK-001, a late-stage oral candidate for Stargardt disease.
• ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial, with topline data expected in 2029.
• The program carries FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations for Stargardt disease.
• The deal was announced on Aug. 6, 2026, then closed following satisfaction of customary closing conditions under the merger agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609040838PRIMZONEFULLFEED9821614) on September 04, 2026, and is solely responsible for the information contained therein.